Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Pathologic considerations and standardization in mesothelioma clinical trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30502-7. doi: 10.1016/j.jtho.2019.06.020. [Epub ahead of print]

PMID:
31260832
2.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15.

PMID:
31103412
3.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
4.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

5.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
6.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
7.

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.

Fennell DA.

J Thorac Oncol. 2018 Oct;13(10):1436-1437. doi: 10.1016/j.jtho.2018.07.007. No abstract available.

PMID:
30244849
8.

Targeting the tumour vasculature in mesothelioma.

Fennell DA.

Lancet Oncol. 2018 Jun;19(6):723-724. doi: 10.1016/S1470-2045(18)30248-1. Epub 2018 May 9. No abstract available.

PMID:
29753701
9.

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.

Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, Ottensmeier C, Barnes D, Hill S, Kalevras M, Maishman T, Griffiths G.

Trials. 2018 Apr 18;19(1):233. doi: 10.1186/s13063-018-2602-y.

10.

BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.

11.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

12.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.

PMID:
29444986
13.

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.

Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.

14.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
15.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
16.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL.

Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.

PMID:
28729154
17.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

18.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

19.

How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?

Sharkey AJ, O'Byrne KJ, Nakas A, Tenconi S, Fennell DA, Waller DA.

Lung Cancer. 2016 Oct;100:5-13. doi: 10.1016/j.lungcan.2016.07.023. Epub 2016 Jul 22.

PMID:
27597274
20.

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.

21.

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D.

Cancer Treat Rev. 2016 Mar;44:42-50. doi: 10.1016/j.ctrv.2016.01.003. Epub 2016 Feb 4. Review.

PMID:
26866673
22.

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW.

Cell Mol Life Sci. 2016 Mar;73(6):1209-24. doi: 10.1007/s00018-015-2117-6. Epub 2016 Jan 11. Review.

23.

Circumventing HSP90 inhibitors via apoptosis block.

Fennell DA, Busacca S.

Oncoscience. 2015 Aug 20;2(9):747-8. eCollection 2015. No abstract available.

24.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

25.

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

26.

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.

Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME.

Eur J Cancer. 2014 Nov;50(16):2771-82. doi: 10.1016/j.ejca.2014.07.020. Epub 2014 Aug 21.

PMID:
25155251
27.

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.

Richards MW, Law EW, Rennalls LP, Busacca S, O'Regan L, Fry AM, Fennell DA, Bayliss R.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5195-200. doi: 10.1073/pnas.1322892111. Epub 2014 Mar 24.

28.

Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly.

Majkut J, Sgobba M, Holohan C, Crawford N, Logan AE, Kerr E, Higgins CA, Redmond KL, Riley JS, Stasik I, Fennell DA, Van Schaeybroeck S, Haider S, Johnston PG, Haigh D, Longley DB.

Nat Commun. 2014 Feb 28;5:3350. doi: 10.1038/ncomms4350.

29.

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.

Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB.

Cell Death Dis. 2013 Dec 5;4:e951. doi: 10.1038/cddis.2013.481.

30.

The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis.

McFarlane C, McFarlane S, Paul I, Arthur K, Scheaff M, Kerr K, Stevenson M, Fennell DA, Johnston JA.

Oncotarget. 2013 Oct;4(10):1836-43.

31.

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.

Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L.

Oncogenesis. 2013 Sep 23;2:e72. doi: 10.1038/oncsis.2013.32.

32.

SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.

Crawford N, Stasik I, Holohan C, Majkut J, McGrath M, Johnston PG, Chessari G, Ward GA, Waugh DJ, Fennell DA, Longley DB.

Cell Death Dis. 2013 Jul 18;4:e733. doi: 10.1038/cddis.2013.258.

33.

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].

34.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

35.

Apoptotic agents.

Fennell DA.

Transl Lung Cancer Res. 2013 Jun;2(3):238-43. doi: 10.3978/j.issn.2218-6751.2013.01.03. Review. No abstract available.

36.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
37.

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ.

PLoS One. 2013;8(1):e54193. doi: 10.1371/journal.pone.0054193. Epub 2013 Jan 17.

38.

Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC.

PLoS One. 2012;7(12):e52753. doi: 10.1371/journal.pone.0052753. Epub 2012 Dec 26.

39.

Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.

Paul I, Chacko AD, Stasik I, Busacca S, Crawford N, McCoy F, McTavish N, Wilson B, Barr M, O'Byrne KJ, Longley DB, Fennell DA.

Cell Death Dis. 2012 Dec 20;3:e449. doi: 10.1038/cddis.2012.186.

40.

Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.

Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, O'Byrne KJ, Meerbeeck JV, Donnellan P, McCaffrey J, Baas P.

J Thorac Oncol. 2012 Sep;7(9):1466-70.

41.

Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.

Fennell DA, Swanton C.

EPMA J. 2012 Jun 18;3(1):6. doi: 10.1186/1878-5085-3-6.

42.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
43.

Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.

Yuen HF, McCrudden CM, Grills C, Zhang SD, Huang YH, Chan KK, Chan YP, Wong ML, Law S, Srivastava G, Fennell DA, Dickson G, El-Tanani M, Chan KW.

Cancer Sci. 2012 Jun;103(6):1145-54. doi: 10.1111/j.1349-7006.2012.02252.x. Epub 2012 Apr 3.

44.

Implications for powering biomarker discovery studies.

Dibben SM, Holt RJ, Davison TS, Wilson CL, Taylor J, Paul I, McManus K, Kelly PJ, Proutski V, Harkin DP, Kerr P, Fennell DA, James JA, Kennedy RD.

J Mol Diagn. 2012 Mar-Apr;14(2):130-9. doi: 10.1016/j.jmoldx.2011.10.002. Epub 2012 Jan 15.

PMID:
22251612
45.

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2012 Jun;227(2):200-8. doi: 10.1002/path.3979. Epub 2012 Mar 19.

PMID:
22190288
46.

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM, Busacca S, Barbone D, Broaddus VC, Gray SG, O'Byrne KJ, Johnston PG, Fennell DA, Longley DB.

Eur J Cancer. 2012 May;48(7):1096-107. doi: 10.1016/j.ejca.2011.11.009. Epub 2011 Dec 10.

PMID:
22154545
47.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

48.

A TMA de-arraying method for high throughput biomarker discovery in tissue research.

Wang Y, Savage K, Grills C, McCavigan A, James JA, Fennell DA, Hamilton PW.

PLoS One. 2011;6(10):e26007. doi: 10.1371/journal.pone.0026007. Epub 2011 Oct 7.

49.

Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery.

Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB, Scott CJ.

Biomaterials. 2011 Nov;32(33):8645-53. doi: 10.1016/j.biomaterials.2011.07.065. Epub 2011 Aug 27.

PMID:
21875750
50.

Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer.

Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, El-Tanani M.

Br J Cancer. 2011 Aug 9;105(4):542-51. doi: 10.1038/bjc.2011.269. Epub 2011 Jul 19.

Supplemental Content

Loading ...
Support Center